Health TrialsbyHealthPanel

Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections

ConditionImmunocompromised ICU Patients With Respiratory Tract Infections
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNew Valley University

About this trial

Immunocompromised individuals face a heightened risk of life-threatening fungal infections, which arise from a multitude of environmental and commensal fungi. Surveillance data from ICUs worldwide identifies Candida spp. as the dominant foe, responsible for 80% of such infections, earning it the dubious distinction of being the third most prevalent pathogen. While C. albicans holds the dubious crown as the most common Candida offender, recent years have witnessed a concerning trend toward non-Albicans candida, raising concerns about potential antifungal resistance.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

All adult patients (aged >18 years old) admitted to the Assiut University Hospital's intensive care units with pneumonia and hospitalized patients who developed hospital-acquired or ventilator-associated pneumonia who don't respond to antibiotics for 48 hours or with a CT finding suspected for fungal pneumonia.

Pre-existing lung disease: IPF, COPD, or sarcoidosis.

Immunosuppression: Neutropenia, on corticosteroids, or immunosuppressive drugs, inherited or acquired immunodeficiency.

Underlying comorbidities: (Diabetes Mellitus,Chronic kidney disease, Liver cirrhosis)

Disqualifiers

Patients refused to contribute to the study.

Unsatisfactory sample.

Trial design

Design model

Single group

Treatments tested in this trial

  • Complete blood count

    Diagnostic test

    blood sample

  • C-reactive protein, urea, creatinine, Random blood glucose (RBG), aspartate aminotransferase (AST), alanine aminotransferase (ALT)

    Diagnostic test

    serum sample

  • CT chest

    Radiation

    Computed tomography of the chest

  • Microscopic examination

    Diagnostic test

    sputum and bronchoalveolar lavage (BAL)

  • culture and sensitivity

    Diagnostic test

    for bacterial and fungal

Treatment groups

250 Participants
are divided into 1 treatment group
Group A: Immunocompromised ICU patientsExperimental treatment 5 interventions

Trial outcomes

Primary outcomes

1

Number of fungal species causing pneumonia in immunocompromised ICU patients

Time frame
baseline

Secondary outcomes

1

Determine the antifungal susceptibility profiles of the identified fungal isolates.

Time frame
baseline
2

Number of associated specific patient factors with the type or antifungal resistance of fungal infections

Time frame
baseline

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

New Valley University

Lead sponsor

Source ClinicalTrials.gov
Apply now